Expanded Label News Today

Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

(1) BASEL (dpa-AFX) - Todays Daily Dose brings you news about temporary suspension of bluebird bios gene therapy trials in sickle cell disease, Sesen Bios regulatory catalyst for this year, partial hold on Cortexymes open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimers disease, and expanded FDA approval of Novartis Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as...

BPTH On Steady Path, Cancer Genetics On Watch, GLPG/GILD Scrap IPF Drug, REGNs Libtayo Gets FDA Nod Read on. 1. Bio-Path On A Steady Path Bio-Path Holdings Inc. (BPTH) has been granted the third U.S. patent, expanding the protection of its DNAbilize platform technology that helps to deliver DNA therapeutics directly to cancer cells. In addition, the company is expected to be issued a patent related to its lead product candidate, Prexigebersen, in combination with either a cytidine analogue, su...